3Shoenfeld Y, Toubi E. Protective autoantibodies: role in homeostasis, clinical importance, and therapeutic potential. Arthritis Rheum, 2005,52 (9) : 2599 - 2606.
4Pollet S, Depner T, Moore P, et al. Mesangial glomerulopathy and IgM rheumatoid factor in rheumatoid arthritis. Nephrol, 1989,51(1) : 107 - 111.
5Bonaci-Nikolic B,Nikolic MM,Andrejevic S,et al.Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs:comparison with idiopathic ANCA vasculitides.Arthritis Res Ther,2005,7(5):1072-1081.
6Fujieda M,Hattori M,Kurayama H,et al.Clinical features and outcomes in children with antineutrophil cytoplasmic autoantibody-positive glomerulonephritis associated withpropylthiouracil treatment.J Am Soc Nephrol,2002,13(2):437-445.
7Dolman KM,Gans RO,Vervaat TJ,et al.Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy.Lancet,1993,342(8872):651-652.
8Huang CN,Hsu TC,Chou HH,et al.Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves' disease treated with propylthiouracil or methimazole in Taiwan.J Formos Med Assoc,2004,103(4):274-279.
9Gumà M,Salinas I,Reverter JL,et al.Frequency of antineutrophil cytoplasmic antibody in Graves' disease patients treated with methimazole.J Clin Endocrinol Metab,2003,88(5):2141-2146.
10Kawasaki Y,Suzuki J,Sike T,et al.A pediatric case of myeloperoxidase-antineutrophil cytoplasmic (ANCA)-related crescentic glomerulonephritis associated with propylthiouracil treatment for Graves' disease.Nippon Jinzo Gakkai Shi,1998,40(8):612-617.
